Statistics
Publications
198
Citations
31.7K
H-Index
68
Active since
1998
Mario Mandalà is an author at Ospedale Papa Giovanni XXIII specializing in medicine, oncology, and radiation oncology.
Publications per year
1998–2024
198
198
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
James Larkin, Paolo A. Ascierto, Brigitte Dréno et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · New England Journal of Medicine · 2014 · 1.8K citations · Full text
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.8K citations · Full text
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
Georgina V. Long, Axel Hauschild, Mario Santinami et al. · New England Journal of Medicine · 2017 · 1.4K citations · Full text
1–5 of 198